About Us
Research Watch
नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकटFrontline Perspectives on Nursing Leadership in NepalProtecting the Smallest Lungs from the Hidden Grip of RSV in KathmanduThe Heavy Burden of Bullying on Student Wellbeing in NepalThe Emerging Landscape of Thyroid Health in Central NepalHow a Recent Western Nepal Study is Redefining Anemia DiagnosisHow H. Pylori is Impacting the Health of Karnali’s High-Altitude CommunitiesSweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s YouthHow Missing Checklists and Protocols are Costing Lives in Nepal’s ERsWhy Your Lungs May Hold the Secret to Your Stress Levelsनेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकटFrontline Perspectives on Nursing Leadership in NepalProtecting the Smallest Lungs from the Hidden Grip of RSV in KathmanduThe Heavy Burden of Bullying on Student Wellbeing in NepalThe Emerging Landscape of Thyroid Health in Central NepalHow a Recent Western Nepal Study is Redefining Anemia DiagnosisHow H. Pylori is Impacting the Health of Karnali’s High-Altitude CommunitiesSweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s YouthHow Missing Checklists and Protocols are Costing Lives in Nepal’s ERsWhy Your Lungs May Hold the Secret to Your Stress Levels

Randomized Clinical Trials Using a Hierarchical Composite Primary End Point: A Scoping Review.

Researchers

Selina Ehrenzeller, Amos J de Jong, Yonas Martin, Marlieke E A de Kraker, Holly Jackson, Nasreen Hassoun-Kheir, Michaela Schumacher, Nadine Saskia Bernasconi, Marjolein P M Hensgens, Christian Appenzeller-Herzog, Natalie Rose, Steven Y C Tong, Nina Khanna, Richard Kuehl, Matthias Briel, Sean W X Ong, Benjamin Speich

Abstract

Hierarchical composite end points (HCEs) are a promising tool used in randomized clinical trials (RCTs) to integrate multiple outcomes of varying clinical relevance into a single measure. To describe how often HCEs are used as primary outcomes in RCTs, and how they are constructed, analyzed, and reported. MEDLINE, Embase, CENTRAL, and Web of Science were searched on December 9, 2024, complemented by a forward citation search of methodological papers on HCEs. RCTs that used an HCE as their primary outcome were included, defined either by self-declaration (hierarchical composite or outcome ranking) or through use of an HCE-specific analytical approach (win ratio, win odds, probabilistic index, or generalized pairwise comparison). Pilot studies, post hoc analyses, and hierarchically tested coprimary end points were excluded. Data were independently screened and extracted in duplicate. Trial characteristics, end point composition, hierarchy justification, and analytical methods were summarized descriptively. Among 5188 screened records, 92 RCTs were included, with 79 567 planned participants. The use of an HCE as a primary end point has increased, with 72 trials (78.3%) initiating recruitment within the past decade. Most RCTs were drug trials (43.5% [40 of 92]), in cardiology (43.5% [40 of 92]), multicenter (91.3% [84 of 92]), and non-industry sponsored (67.4% [62 of 92]). The 92 HCEs had a median (IQR) of 4 (3-5) components and the highest ranked component was usually mortality (80.4% [74 of 92]). The last hierarchical component was most often a continuous component (64.1% [59 of 92]). The majority of RCTs did not report any information on how the hierarchy was established (82.2% [60 of 73]; excluding RCTs where only information from registries was available). Generalized pairwise comparison was the most frequent analysis approach (57.3% [26 of 45]) among the 45 published RCTs, yet no standardized way for presenting results was observed. This scoping systematic review of 92 RCTs using HCEs found that their use has increased across medical fields, but their construction, analytical approaches, and reporting of results remained highly heterogeneous. By systematically mapping how HCEs are currently implemented, further review is essential for the development of much needed methodological and reporting standards.
Source: PubMed (PMID: 42518231)View Original on PubMed